Literature DB >> 20191478

Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis.

Mikkel Faurschou1, Lene Dreyer, Anne-Lise Kamper, Henrik Starklint, Søren Jacobsen.   

Abstract

OBJECTIVE: To evaluate the long-term mortality and renal outcome in a cohort of Danish patients with lupus nephritis (LN) and to identify outcome predictors among findings registered at the time of the first renal biopsy.
METHODS: The cohort consisted of 100 patients diagnosed with LN (World Health Organization classes I-VI) between 1971 and 1995 and followed for a median duration of 14.7 years (range 0.01-36.9 years). Standardized mortality ratios (SMRs) were calculated on the basis of national age-, sex-, and calendar-year period-specific death rates.
RESULTS: Thirty-seven deaths occurred in the cohort, corresponding to an overall SMR of 6.8 (95% confidence interval [95% CI] 4.9-9.4). Excess mortality was observed throughout followup. The SMR estimates were 9.0 (95% CI 4.7-17.1), 6.2 (95% CI 4.0-9.5), and 6.6 (95% CI 3.1-13.8) for patients diagnosed during the calendar-year periods 1971-1979, 1980-1989, and 1990-1995, respectively. The cumulative renal survival after 5, 10, and 20 years of followup was 87%, 83%, and 73%, respectively. The risk of end-stage renal disease (ESRD) did not decrease significantly across calendar-year periods. Systolic blood pressure >or=180 mm Hg, focal segmental nephritis, and advanced sclerosing nephritis were identified as baseline predictors of death in multivariate regression analyses, while systolic blood pressure >or=180 mm Hg, serum creatinine level >or=140 mumoles/liter, and diagnostic delay predicted progression to ESRD.
CONCLUSION: LN is associated with excess long-term mortality, and patients may progress to ESRD even after prolonged followup. Our analyses indicate that focal segmental histopathology at disease onset constitutes an important risk factor for death among LN patients. Moreover, our data underscore the importance of early intervention, blood pressure control, and long-term followup in LN.

Entities:  

Mesh:

Year:  2010        PMID: 20191478     DOI: 10.1002/acr.20116

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  53 in total

1.  P2X7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3/ASC/caspase 1 pathway.

Authors:  Jijun Zhao; Hongyue Wang; Chao Dai; Hongyang Wang; Hui Zhang; Yuefang Huang; Shuang Wang; Felicia Gaskin; Niansheng Yang; Shu Man Fu
Journal:  Arthritis Rheum       Date:  2013-12

2.  Undertreatment of disease activity in systemic lupus erythematosus patients with endstage renal failure is associated with increased all-cause mortality.

Authors:  Anna Broder; Saakshi Khattri; Ruchika Patel; Chaim Putterman
Journal:  J Rheumatol       Date:  2011-09-01       Impact factor: 4.666

3.  [Protective effects of glycyrrhizic acid against lupus nephritis in MRL/lpr mice].

Authors:  Yuan-Yuan Wang; Hong-Tao Li; Yang Lu; Xiao-Yun Jia; Yang-Lei Li; Sheng Chen; Ji-Xia Chai; Jia-Jia Zhang; Dong Liu; Chang-Hao Xie
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-07-20

4.  Clinicopathological and outcome analysis of adult lupus nephritis patients in China.

Authors:  Yi Tang; XiaoYan Zhang; Ling Ji; XuHua Mi; Fei Liu; LiChuan Yang; Wei Qin
Journal:  Int Urol Nephrol       Date:  2015-01-07       Impact factor: 2.370

5.  Enteric-coated mycophenolate sodium in pediatric lupus nephritis: a retrospective cohort study.

Authors:  Hsin-Hsu Chou; Mei-Ju Chen; Yuan-Yow Chiou
Journal:  Clin Exp Nephrol       Date:  2015-10-20       Impact factor: 2.801

6.  Plasma ficolin levels and risk of nephritis in Danish patients with systemic lupus erythematosus.

Authors:  Nima Tanha; Katrine Pilely; Mikkel Faurschou; Peter Garred; Søren Jacobsen
Journal:  Clin Rheumatol       Date:  2016-12-15       Impact factor: 2.980

7.  Treatment Delays Associated With Prior Authorization for Infusible Medications: A Cohort Study.

Authors:  Zachary S Wallace; Tyler Harkness; Xiaoqing Fu; John H Stone; Hyon K Choi; Rochelle P Walensky
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-11       Impact factor: 4.794

Review 8.  The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis.

Authors:  Marcus R Clark; Kimberly Trotter; Anthony Chang
Journal:  Semin Nephrol       Date:  2015-09       Impact factor: 5.299

Review 9.  Update on Lupus Nephritis.

Authors:  Salem Almaani; Alexa Meara; Brad H Rovin
Journal:  Clin J Am Soc Nephrol       Date:  2016-11-07       Impact factor: 8.237

Review 10.  Recent clinical trials in lupus nephritis.

Authors:  Michael M Ward
Journal:  Rheum Dis Clin North Am       Date:  2014-06-07       Impact factor: 2.670

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.